-

Altasciences Receives 2024 CRO Leadership Award for Capabilities

LAVAL, Québec--(BUSINESS WIRE)--Altasciences announced today that it has been recognized for excellence in contract research with a 2024 CRO Leadership Award for Capabilities. This marks the ninth year that Altasciences, a fully integrated drug development solution company, has been deemed a top performer.

Clinical Leader and Life Science Leader teamed up with ISR Reports to assess 42 CROs on more than 20 performance metrics in ISR’s annual CRO Quality Benchmarking survey. Survey respondents are qualified and only evaluate companies with which they have worked on an outsourced project within the past 18 months.

“For 12 years, Life Science Connect has been working alongside ISR Research to develop our annual CRO Leadership Awards. Receiving one of these awards is a testament to a company’s relentless pursuit of providing the highest standard of service to the clinical research industry, and we congratulate the winners on all their hard work,” said Dan Schell, Chief Editor, Clinical Leader.

The Capabilities category assesses respondents on a CRO’s ability to deliver a wide range of services, expertise, and resources across multiple therapeutic areas. Altasciences has transformed the traditional outsourcing paradigm by building a one-stop outsourcing solution with end-to-end services that simplify and safely accelerate the early-phase drug development process for its clients.

We are honored to have been recognized as a leader in the CRO industry. Our mission has always been to provide the highest quality early-stage drug development solutions, with personalized services and a focus on efficiency. These awards recognize and validate our employees' daily efforts to achieve our goal. I am incredibly proud of our team, said Chris Perkin, CEO at Altasciences.

With nine strategically placed research and manufacturing facilities across North America, Altasciences helps safely accelerate its clients’ life-changing therapeutics from lead candidate selection to clinical proof of concept, and beyond.

About Altasciences

Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.

Contacts

Julie-Ann Cabana
Altasciences
+1 514 601-9763
jcabana@altasciences.com

More News From Altasciences

Altasciences and Evidence Matters Announce Strategic Collaboration to Advance AI-Enhanced Text Engineering for Regulatory Writing in Life Sciences

LAVAL, Québec--(BUSINESS WIRE)--Altasciences, a fully integrated CRO/CDMO offering comprehensive early-phase drug development solutions, is pleased to announce a strategic collaboration with Evidence Matters, a pioneer in clinical trial data science and document engineering. This partnership combines Altasciences' real-world drug development expertise with Evidence Matters' innovative, patent-pending Text Engineering technology—a breakthrough that delivers near-deterministic accuracy in regulat...

Altasciences Chosen by Steel Therapeutics to Support the Launch of Pivotal Toxicology Study for Fizurex™

LAVAL, Québec--(BUSINESS WIRE)--Altasciences is pleased to have been chosen by Steel Therapeutics, Inc. (“Steel”), to initiate a pivotal toxicology study for Fizurex™, a novel topical therapy for the treatment of anal fissures. The GLP-compliant study is currently being conducted at Altasciences’ preclinical facility in Columbia, MO. It marks a key milestone in Steel’s regulatory development, as the company prepares for an Investigational New Drug (IND) application in early 2026. “We’re proud t...

Altasciences Receives EcoVadis Gold Medal for Environmental, Social, and Governance (ESG) Efforts

LAVAL, Québec--(BUSINESS WIRE)--Altasciences is proud to announce that it has received a sustainability Gold Medal from EcoVadis, placing the contract research organization (CRO) in the 96th percentile and among the top 5% of companies evaluated globally. EcoVadis, the world’s most trusted provider of business sustainability ratings, has collaborated closely with Altasciences to enhance its environmental, social, and governance (ESG) initiatives, underscoring the company’s commitment to a susta...
Back to Newsroom